Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 26, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

ICRISAT Biological Science Research Technician Vacancy Available

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER
  • BiotechToday
  • World

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

bioxone December 2, 2020December 2, 2020

Husna, Amity University Kolkata

Oncolytic viruses are genetically engineered for the destruction of cancer or tumour-causing cells specifically. They’re delivered for treatment inside the body via intravenous injection. In 2015, one such oncolytic virus was approved by the FDA for treating skin cancer, melanoma. A major obstacle in the application of oncolytic adenoviruses is that they face a barrier from the human immune system. The antibodies and blood components neutralize the injected adenovirus doses and also send it to the liver, the body’s garbage disposal. Some patients also developed inflammation and infection reaction on the application of oncolytic adenovirus.

Recently these barriers have been overcome by the researchers from the Pharmacology department of Case Western Reserve University. They’ve re-engineered the human adenovirus in such a way that it doesn’t get caught by parts of the innate immune system easily. Dmitry Shayakhmetov, PhD has stated that now it is possible to deliver the modified virus systemically at possible high doses for suppression of the tumour growth and even the life-threatening systemic toxicities or inflammatory reaction won’t get triggered anymore. Furthermore, the re-engineered adenoviruses can be armed with genes and proteins that can stimulate an immunity to cancer. 

The re-engineered adenovirus is therefore a technology which can be customized for various cancer patients and can be used as personalized life-saving therapy to patients with metastatic cancer.  

Also read:None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

SOURCE: 

https://scitechdaily.com/new-weapon-against-metastatic-cancer-engineered-stealth-bomber-virus/

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged adenovirus cancer engineered oncolytic adenovirus FDA infections inflammation inflammatory reactions injection innate immune system intravenously melanoma metastasis metastatic cancer oncolytic patients skin cancer technology therapy tumour cells tumour growth weapon

4 thoughts on “ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER”

  1. Diwita Roy says:
    December 2, 2020 at 4:00 pm

    Very well written. Illuminating content.

    Reply
  2. Pingback: DRY SWAB-DIRECT RT-PCR TO RAMP UP TEST FREQUENCY - BioXone
  3. sania says:
    December 3, 2020 at 11:23 am

    👍well written

    Reply
  4. Fathima Nifara says:
    December 7, 2020 at 1:54 pm

    As Iam very much interested in cancer biology, I personally like this article and its written in a very comprehensible manner.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

ICRISAT Biological Science Research Technician Vacancy Available

bioxone December 3, 2020

-Shristi Sharma, Team bioXone ICRISAT Biological Science Research Technician Vacancy Available. ICRISAT hiring for research vacancies for BSc Biological Sciences candidates with mentioned qualifications are eligible. Check out all the details posted below on the same:  Name of Job: Research Technician No. of Posts: 01 How to Apply: Candidates should apply on or before 17 […]

Related Post

  • BiotechToday
  • World

More about Fractional Response Analysis

bioxone December 18, 2020December 18, 2020

Richismita Hazra, Amity University Kolkata Single-cell signaling responses are now measurable, but their interpretation is still restricted. Interpretation of dose-response based on single-cell data is also not accurately predictable. Here, probabilistic modeling and information-theory have been used to inaugurate fractional response analysis (FRA). This technique quantifies changes in the fraction of cells with provided response […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Recent insights on rearmost Dinosaur footprints in the UK

BioTech Today June 24, 2021June 23, 2021

Varuni Ankolekar, Clinical Data Manager at Quartesian A thrilling discovery by Martill and group has declared to have found the footprints of at least six distinct dinosaur species of the rearmost dinosaurs to walk on UK soil 110 million years ago in Kent. It was intriguing for them to find such an array of species […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Brain connections in auto-linking of objects to our mind

BioTech Today July 18, 2021July 18, 2021

Sarah Khatkhatay, SK Somaiya Vidhyadhar A mind, a soul, and a spirit. Within our bodies, a central role is played by the nervous system from receiving information from the sensory organs to controlling muscle movement. But, what is a mind, its nature, and what role does it play? Most of us believe that the mind […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy